Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies.

Claus Bachert,Siddhesh Kamat,Heidi Olze,Zhen Chen,Richa Attre,Shahid Siddiqui,Raj Rout,Oliver Pfaar,Paul J Rowe,Enrico Heffler,Joseph K Han,Juby A Jacob‐Nara,Ledia Goga,Chien‐Chia Chuang,Anju T Peters,Yamo Deniz

doi:10.1111/cea.14051

Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies.

Claus Bachert, Siddhesh Kamat + Show 14 more

Open Access

https://doi.org/10.1111/cea.14051

Copy DOI

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology	Publication Date: Jan 28, 2022
Citations: 7	License type: unspecified-oa

Affiliation: Regeneron (United States), Charité - Universitätsmedizin Berlin, Sanofi (United Kingdom), Philipps University of Marburg, Sun Yat-sen University, Ghent University, Sanofi (United States), Humanitas University, Eastern Virginia Medical School, AVEO Oncology (United States), Northwestern University

#Severe Chronic Rhinosinusitis #Nasal Polyps + Show 2 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Responder analysis to demonstrate the effect of targeting type 2 inflammatory mechanisms with dupilumab across objective and patient-reported endpoints for patients with severe chronic rhinosinusitis with nasal polyps in the SINUS-24 and SINUS-52 studies.

Full Text